Glatiramer acetate

Copaxone, Glatopa (generic), glatiramer acetate, copolymer-1 (Cop-1), COP-1

Immune & bioregulators

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. Glatiramer acetate is an approved prescription medicine for multiple sclerosis, not a research-only compound. This page explains the published science. It carries a boxed warning for anaphylaxis (added in the US in January 2025) and is used only under neurological care; it is not a self-directed peptide.

Summary

Class: A synthetic, deliberately random mixture of polypeptides made from four amino acids (L-glutamate, L-lysine, L-alanine, L-tyrosine) in fixed molar ratios — not a single defined peptide
Mechanism: Thought to shift the immune response away from attacking myelin — inducing regulatory/anti-inflammatory T cells and acting as a decoy resembling myelin basic protein
Routes studied: Subcutaneous injection
Half-life: Not a conventional pharmacokinetic drug — it is largely hydrolysed locally at the injection site; a classical plasma half-life does not apply
Storage: Prefilled syringes; refrigerate, may be kept at room temperature for a limited period per label
Regulatory status: Approved (US, EU, UK, AU, ZA and widely) for relapsing MS; generics available

Doses are as reported in studies or by the community — never recommendations.

1What it is

Glatiramer acetate is one of the most unusual approved medicines in this reference. It is not a single peptide but a controlled random mixture of polypeptide chains, synthesised from just four amino acids (glutamate, lysine, alanine, tyrosine) in fixed proportions, with a range of chain lengths. It was designed in the 1960s–70s to resemble myelin basic protein, a component of the myelin sheath that the immune system attacks in multiple sclerosis. The idea was originally to induce an MS-like disease in animals; instead the mixture suppressed it, and it became a disease-modifying therapy.

It is a widely used prescription MS drug (brand Copaxone, generic Glatopa), given by self-injection but prescribed and supervised by neurologists. It belongs here as the classic example of an approved "polypeptide" immunomodulator, not as a community research compound.

2How it's thought to work

The mechanism is still not fully pinned down, which is itself notable for a drug used for decades:

Immune deviation. it is thought to shift myelin-reactive T cells from a pro-inflammatory (Th1) toward an anti-inflammatory/regulatory (Th2, Treg) profile.

Decoy/competition. resembling myelin basic protein, it may compete for presentation to T cells and blunt the autoimmune attack.

Bystander suppression. glatiramer-specific T cells may migrate to the central nervous system and release anti-inflammatory signals locally.

Neuroprotection. some evidence suggests increased production of neurotrophic factors (e.g. BDNF).

A random mixture of four amino acids resembling myelin basic protein. Given daily, it is thought to divert the T-cell response in multiple sclerosis towards a regulatory one.Schematic — not to scale

3What the research shows

Relapsing-remitting MS

Multiple established that glatiramer acetate 20 mg daily reduces relapse rate and MRI lesion activity versus placebo, with benefit sustained in long-term follow-up (Johnson 1995, Neurology and the pivotal programme). [1]

Three-times-weekly 40 mg dosing

The GALA trial (Khan 2013, Ann Neurol) showed that 40 mg three times weekly significantly reduced relapses and MRI activity versus placebo, giving the more convenient regimen now widely used. [2]

Comparative efficacy

Head-to-head and network comparisons place glatiramer among the established first-line injectable disease-modifying therapies (comparable to interferon-beta), generally less potent than newer high-efficacy agents but with a long, reassuring safety record.

Clinically isolated syndrome

The PreCISe trial showed glatiramer delayed conversion to clinically definite MS in people with a first demyelinating event.

Graded A (negative)

Progressive MS

Trials in primary progressive MS did not show meaningful benefit; its role is in relapsing disease.

4Reported side effects and interactions

Literature-reported

Literature. the characteristic adverse effects are injection-site reactions (redness, pain, lumps, and occasionally lipoatrophy — permanent dents in the fat under the skin) and a transient immediate post-injection reaction (flushing, chest tightness, palpitations, shortness of breath, anxiety) that typically resolves in 15–30 minutes and is usually benign.

Serious / warnings. the FDA added a boxed warning for anaphylaxis in January 2025 after reviewing 82 serious anaphylaxis cases worldwide (1996–2024), including hospitalisations and six deaths; anaphylaxis can occur after the first dose or years into treatment, and its early symptoms can be confused with the common, benign post-injection reaction. The drug should be stopped and not restarted if anaphylaxis occurs.

Community-reported

Community/self-directed use outside MS care: essentially none documented. It is a prescribed self-injected medicine, not a biohacking peptide.

Theoretical. because it modulates immunity, its interplay with other immunotherapies is considered, though it is not broadly immunosuppressive and does not raise infection risk the way some MS drugs do.

Interactions. no major pharmacokinetic interactions (it is not systemically absorbed as intact drug); the practical issue is overlap of post-injection reaction symptoms with anaphylaxis.

Markers researchers commonly monitor

Reflecting MS care rather than routine lab toxicity (glatiramer needs relatively little laboratory monitoring compared with other MS drugs):

Marker	Why it's watched
Clinical relapse rate and neurological examination	the primary measure of benefit.
MRI lesion activity	the imaging measure of disease control, checked periodically.
Injection-site inspection	for lipoatrophy and recurrent reactions.
Signs of anaphylaxis / post-injection reaction	clinical vigilance, now emphasised by the boxed warning.
No routine blood count or liver monitoring is mandated for glatiramer itself, unlike several other MS therapies

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Supplied as prefilled syringes (20 mg/mL daily; 40 mg/mL three-times-weekly) — no . Rotating injection sites is standard advice to reduce site reactions and lipoatrophy; follow the product label and prescriber guidance.

6Commonly studied alongside

Interferon-beta (comparator first-line injectable), newer oral and infused MS disease-modifying therapies (as comparators, not combinations), vitamin D and standard MS supportive care.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	FDA-approved (Copaxone; generic Glatopa and others); boxed warning for anaphylaxis added January 2025
European Union	EMA/national authorisation for relapsing MS; generics available
United Kingdom	MHRA-licensed; prescription-only
Australia	TGA-approved
South Africa	SAHPRA-registered
Sport	Not prohibited by WADA (a disease-modifying immunomodulator, not a performance substance)

8Open questions

What is the precise mechanism — after decades of use it remains only partly understood?
Can biomarkers predict who responds to glatiramer versus who needs a higher-efficacy therapy?
How is the newly characterised anaphylaxis risk best anticipated, given it can appear years into treatment?

9References

1Johnson KP et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology. DOI
2Khan O et al. (2013). Three times weekly glatiramer acetate in relapsing-remitting MS (GALA study). Ann Neurol. PubMed
3Comi G et al. (2009). Effect of glatiramer acetate on conversion to clinically definite MS in patients with a first demyelinating event (PreCISe). Lancet. PubMed
4US FDA (2025). Drug Safety Communication: boxed warning about anaphylaxis with glatiramer acetate (Copaxone, Glatopa). PubMed
5Copaxone / Glatopa prescribing information (current label). PubMed

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

30 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.